Lite Strategy (LITS) Net Margin Growth (5y) (2021 - 2023)
Powered by 
Analysis
Lite Strategy (LITS) Net Margin Growth (5y) (2021 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 306,625.00 |
| Jun 30, 2023 | 282,581.00 |
| Mar 31, 2023 | 111,181.00 |
| Dec 31, 2022 | 172,789.00 |
| Sep 30, 2022 | 290,210.00 |
| Jun 30, 2022 | 82,717.00 |
| Mar 31, 2022 | -20,840.00 |
| Dec 31, 2021 | -21,797.00 |
| Sep 30, 2021 | 13,052.00 |